Expert Interview
Discussing the proposed National Coverage Determination (NCD) on renal denervation, applicable to Medtronic's Symplicity Spyral™ renal denervation (RDN) system
Ticker(s): MDTInstitution: University of Vermont Health
- Interventional cardiologist based in South Burlington, Vermont, affiliated with the University of Vermont Medical Center.
- Received his medical degree from the University of North Carolina at Chapel Hill School of Medicine and has 11–20 years of clinical experience.
- Specializes in coronary artery disease, structural heart disease, aortic stenosis, mitral valve regurgitation, and angina, with expertise in TAVR and PCI.
- Actively involved in clinical trials and database research focused on interventional cardiology and heart valve therapies.
How many renal denervation procedures do you perform annually?
Added By: nick_adminOn a scale of 1–10, how big of a shift could CMS coverage for RDN represent for resistant hypertension treatment in the next 2–3 years?
Added By: nick_adminOnce CMS finalizes national coverage, how quickly do you expect commercial insurers to follow with coverage decisions?
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Oct 29, 2025
- Call Time
- 08:00 AM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
